Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Cisplatin + Gemcitabine
DRUG
2 trials
Sponsors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
, AstraZeneca
Conditions
Metastatic Urothelial Cancer
Non-small Cell Lung Cancer Metastatic
Unresectable Locally Advanced Urothelial Cancer
Phase 2
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
Terminated
NCT01752023
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-small Cell Lung Cancer Metastatic
Start: 2013-03-31
End: 2014-04-30
Updated: 2018-10-17
Phase 3
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Active, not recruiting
NCT03682068
AstraZeneca
Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
Start: 2018-09-27
End: 2027-06-01
Updated: 2026-08-20
Related Papers
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
British Journal of Cancer
2023-02-16
13 citations
A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE).
Journal of Clinical Oncology
2021-02-20
28 citations
Antibodies to watch in 2020.
2020-01-01
328 citations
A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
Journal of Clinical Oncology
2019-05-20
5 citations
A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
Journal of Clinical Oncology
2019-03-01
8 citations